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INTRODUCTION
We have shown that postgrafting immunosuppression,
which is given after conventional hematopoietic stem cell
transplantation (HSCT) to prevent acute graft-versus-host
disease (GVHD) [1,2], plays a key role in donor engraft-
ment of nonmyeloablated canine transplant recipients [3].
This result is achieved by controlling host-versus-graft
reactions and thereby assisting in avoiding graft rejection.
A regimen consisting of mycophenolate mofetil (MMF)
given for 28 days and cyclosporine (CSP) for 35 days
allowed the single dose of pretransplantation total body
irradiation (TBI) needed for durable engraftment of dog
leukocyte antigen (DLA)-identical marrow to be decreased
from 920 cGy to the sublethal level of 200 cGy [3]. A fur-
ther reduction of TBI to 100 cGy in this model resulted in
rejection of marrow grafts within 3 to 12 weeks in all 6 dogs
studied [3]. Here, we asked whether stable hematopoietic
engraftment could be achieved in dogs conditioned with
100 cGy TBI, (1) by substituting recombinant canine gran-
ulocyte-colony–stimulating factor–mobilized peripheral
blood mononuclear cells (G-PBMCs) for marrow in recipi-
ents given MMF for 28 days and CSP for 35 days and (2)
by extending CSP administration from 35 to 100 days in
G-PBMC recipients.
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ABSTRACT
Stable mixed donor/host hematopoietic chimerism was uniformly achieved in dogs given 200 cGy total body irradia-
tion (TBI) before and immunosuppression with mycophenolate mofetil (MMF) for 28 days and cyclosporine (CSP)
for 35 days after transplantation of marrow from dog leukocyte antigen–identical littermates. When the TBI dose
was lowered to 100 cGy, donor marrow engraftment in 6 dogs was only transient, lasting 3 to 12 weeks. In this
study, we asked whether stable engraftment in this model could be achieved: (1) by substituting recombinant canine
granulocyte-colony–stimulating factor–mobilized peripheral blood mononuclear cells (G-PBMCs) for marrow and
(2) by extending CSP administration from 35 to 100 days. Eighteen dogs were given G-PBMC grafts and MMF for
28 days. Eight of the 18 dogs received CSP for 35 days and 10 for 100 days. We found that substituting G-PBMCs
for marrow did not increase the incidence of stable allogeneic engraftment (P = .11). However, increasing the dura-
tion of posttransplantation immunosuppression with CSP from 35 to 100 days favorably influenced stable donor
engraftment (P = .06).
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MATERIALS AND METHODS
Study Design
Litters of beagles weighing 7.6 to 16 kg (median, 10.5 kg)
and aged 6 to 15 months (median, 9 months) were used.
Research was conducted according to the principles outlined
in the Guide for Laboratory Animal Facilities and Care (National
Academy of Sciences, National Research Council). The Insti-
tutional Animal Care and Use Committee of the Fred
Hutchinson Cancer Research Center (FHCRC) approved the
research protocol. Kennels were certiﬁed by the American
Association for Accreditation of Laboratory Animal Care.
Selection of DLA-identical donor/recipient pairs was
based on matching for highly polymorphic DLA class I and
class II microsatellite markers as well as gene sequencing for
canine DLA-DRB1 genes [4,5]. Eighteen recipients were
conditioned with 100 cGy TBI (7 cGy/min) from 2 oppos-
ing cobalt-60 sources [6] and given G-PBMC grafts consist-
ing of 5.2 to 13.9 × 108 mononuclear cells/kg (mean, 9.57 ±
3.89 [±1 SD] × 108 cells/kg) from DLA-identical littermates.
The CD34+ cell content was determined in 5 of the dogs
and was found to range from 3.37 to 7.27 × 106 cells/kg
(mean, 4.55 ± 1.61 [±1 SD] × 106 cells/kg). The CD3+ cell
content ranged from 0.5 to 2.54 × 108 cells/kg (mean, 1.67 ±
0.88 [±1 SD] × 108 cells/kg). The technique of G-PBMC
collection has been described in detail [7]. All recipients
were given MMF at 10 mg/kg subcutaneously 2 times daily
(BID) for 28 days after transplantation. Eight of the 18 dogs
received CSP for 35 days at 15 mg/kg orally (PO) BID
(group I) and 10 received CSP for 100 days (15 mg/kg PO
BID for 35 days followed by 7.5 mg/kg BID for 15 days,
5mg/kg BID for 25 days, and 3 mg/kg BID for 25 days)
after transplantation (group II). Posttransplantation care,
assessment of engraftment, and histopathologic examination
were done as previously described [3,8]. Previously pub-
lished results [3] from 6 dogs given 100 cGy TBI at
7 cGy/min from 2 opposing cobalt-60 sources, DLA-identical
marrow grafts (4-4.1 × 108 nucleated marrow cells/kg), and
postgrafting MMF for 28 days and CSP for 35 days served
as controls (group III). CD34+ and CD3+ cell numbers in
the infused marrow grafts were not determined in the his-
torical control dogs. However, in a recent study of 9 similar
marrow-grafted dogs, the mean CD34+ cell dose was 5.96 ±
3.65 (±1 SD) × 106 cells/kg and the CD3+ cell dose was
0.31 ± 0.14 (±1 SD) × 108 cells/kg ([9] and J.M.Z., E.Z.,
R.S., B. Torok-Storb, unpublished data, 2000). Controls
were beagles or harriers, aged 11 to 12 months and weighing
10.2 to 20.0 kg (median, 11.1 kg). Their posttransplantation
care, graft assessment, and histopathologic examination
were standard of care at the FHCRC [3,8] and comparable
to those used in the present study.
RESULTS AND DISCUSSION
Results are shown in the Table. All but 1 of the 8 G-PBMC
recipients in group I given CSP for 35 days had initial
engraftment. Subsequently, 6 of the 7 dogs that had engraft-
ment rejected their grafts between 6 and 22 weeks post-
transplantation and survived with complete autologous
recovery. One dog achieved stable mixed donor/host
chimerism lasting for more than 54 weeks. A comparison of
the duration of engraftment in dogs of group I receiving
G-PBMC with that in the previously reported marrow-
recipient dogs of group III showed no statistically signiﬁcant
difference (log rank test; P = .11). In comparison, 6 of the
10 G-PBMC recipients in group II given CSP for 100 days
rejected their grafts between 4 and 26 weeks posttransplan-
tation, and 4 showed stable mixed chimerism extending
beyond 53 weeks posttransplantation. Comparison of results
in dogs of group II with those of group I strongly suggested
that extending CSP from 35 to 100 days increased duration
of transient and incidence of stable mixed allogeneic
chimerism in this model (P = .06). The difference in results
between groups II and III was highly signiﬁcant (P < .01).
Examples of stable and transient donor engraftment by
microsatellite markers are shown in the Figure.
We conclude that substituting G-PBMCs containing
increased numbers of immunocompetent cells [10] for mar-
row did not overcome graft rejection following conditioning
with 100 cGy TBI in this model. Whether grafts of “mega-
doses” of hematopoietic cells would permit stable engraft-
ment as reported in a swine model [11] is not known,
although data in dogs showing stable engraftment after
100 cGy TBI and postgrafting cyclosporine for 35 days
when marrow and G-PBMCs were combined [9,12] are
consistent with this possibility. Extending postgrafting CSP
from 35 to 100 days facilitated stable donor engraftment in
dogs given G-PBMCs. This result is consistent with previ-
ous observations that induction of graft-host tolerance in a
Results in Dogs Conditioned With 100 cGy Total Body Irradiation and Given Marrow or G-PBMC Grafts From Dog Leukocyte Antigen–Identical Littermates*
Group No. of Source of Duration of CSP Duration of Donor
No. Dogs Stem Cells Treatment, d Engraftment, wk P†
I 8 G-PBMC 35‡ 0, 6, 9, 12, 13, 18, 22, >54 Group I versus II, P = .06
II 10 G-PBMC 100§ 4, 14, 18, 18, 23, 26, >53, >54, >130, >155 Group II versus III, P < .01
III¶ 6 Marrow 35‡ 3, 3, 10, 10, 10, 12 Group III versus I: P = .11
*All recipients received mycophenolate mofetil (MMF), 10 mg/kg subcutaneously 2 times daily (BID), for 28 days after transplantation. G-PBMC
indicates granulocyte-colony–stimulating factor–mobilized peripheral blood mononuclear cells; CSP, cyclosporine.
†Log rank test using combined data for dogs with graft failure and successful grafts; the median engraftment duration was determined using
Kaplan-Meier estimates.
‡CSP, 15 mg/kg BID for 35 days. 
§CSP, 15 mg/kg BID for 35 days followed by 7.5 mg/kg BID for 15 days, 5 mg/kg BID for 25 days, and 3 mg/kg BID for 25 days.
¶Data on these dogs were previously published [3].
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canine acute GVHD model required prolonged postgrafting
immunosuppression [2]. Optimal duration of immunosup-
pressive treatment in nonmyeloablated recipients remains to
be determined. We did not investigate whether a similar
extension of CSP administration would enhance engraft-
ment of marrow grafts in this model.
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Figure 1. Microsatellite marker studies of donor and recipient cells before and recipient cells after hematopoietic stem cell transplantation (HSCT)
in 2 dogs. A, Recipient dog E857 and B, recipient dog E720. Both dogs were conditioned with 100 cGy total body irradiation, received granulocyte-
colony–stimulating factor–mobilized peripheral blood mononuclear cell grafts from their respective dog leukocyte-antigen–identical littermates, and
were given mycophenolate mofetil for 28 days after transplantation. Cyclosporine (CSP) treatment lasted for 35 days in dog E857 (A), whereas CSP
was extended through 100 days in dog E720 (B). Both dogs had initial engraftment; however, dog E857 rejected the graft between week 20 and 23,
whereas dog E720 developed stable mixed donor/host chimerism for >53 weeks. The estimated donor-cell percentage in dog E720 was 90% among
granulocytes and 60% among mononuclear cells.
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